BRCA1 and neoplasm: In the treatment of ovarian cancers, 40–70% of BRCA1/2 mutated patients failed to respond to PARP inhibitors.586 Platinum sensitivity is also reported as a prospective indicator for predicting the response to these inhibitors.587 Nevertheless, these two predictors still cannot completely cover the tumor types suitable for PARP inhibitor treatment.